The Silicon Review
Founded in 1995 as the privately held Impax Pharmaceuticals, Inc, Impax Laboratories is a company of exceptional people, impressive achievements, and exciting potential. Today, the company provide access to affordable, high-quality generics and specialty pharmaceutical products across the U.S.
Focused on leveraging its scientific expertise in drug delivery technologies to develop a niche and controlled release generic products, the company has evolved through organic growth and a series of acquisitions, to become a competitive specialty pharmaceutical company with a growing portfolio of generic and innovative specialty pharmaceutical products.
Providing patients with high-quality medicines is at the heart of what the company does. At Impax, the management recognizes and respect that the company’s work impacts the health and lives of individuals and families. As a result, quality, compliance and continuous improvement are hallmarks of the company, particularly throughout the Generics and Specialty Pharma businesses.
Beyond the commitment of delivering high-quality products for the customers and value for the company’s shareholders, Impax also believes in being a good corporate citizen. The company’s efforts in corporate responsibility include philanthropic donations, volunteerism, sustainable business practices and support for advocacy programs. Across the company, many employees are actively engaged and take pride in supporting important initiatives that provide an opportunity to give back to the communities where they live and work.
The Impax Products
Impax maintains a broad and growing portfolio of medicines that meet patient needs across a wide range of therapeutic categories.
The Impax Generics portfolio currently has more than 60 marketed products that are the pharmaceutical and therapeutic equivalents of various brand-name drug products. These high-quality products provide affordable alternatives for many patients.
The company’s Specialty Pharma portfolios of marketed products are helping to meet critical medical needs in central nervous system disorders, infectious disease, and other therapeutic areas.
Impax serves patients through two key divisions. The Generics business offers an established and growing portfolio of generic pharmaceuticals. The company’s Specialty Pharma business brings new medicines to market in central nervous system disorders, parasitic infections, and other therapeutic categories.
Impax Generics develops, manufactures and commercializes complex oral solids and alternative dosage form products across a broad range of therapeutic categories. The portfolio currently contains more than 60 marketed products, many of which represent difficult-to-manufacture products or products that have a high barrier to entry.
Vision and Values of Impax
The company’s Vision is to build a specialty pharmaceutical company that enhances the lives of the patients, provides challenging and rewarding opportunities for the employees, and creates outstanding value for the customers and stockholders
The Vision is driven by nearly 900 passionate colleagues, who are actively engaged in ensuring the company’s commitment to success, quality, and integrity. A dynamic culture of caring inspires and empowers colleagues to contribute, in a work environment where making a difference is valued.
The values are expressed in a simple, yet meaningful acronym: CARE
Together, the management is growing and reshaping the company, by delivering quality products for patients and making a difference in key social initiatives in the communities and across the company.
About the CEO
Paul M. Bisaro, President and Chief Executive Officer and Director: With 25 years of generic and branded pharmaceutical experience, Mr. Bisaro is an accomplished global business leader. He previously served as Executive Chairman of Allergan, plc (formerly Actavis, plc), President and CEO of Actavis (formerly Watson Pharmaceuticals, Inc.) and Chairman of the Board. Prior to joining Watson in 2007, Mr. Bisaro was President, Chief Operating Officer and a member of the Board of Directors of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company (Barr), from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel of Barr, and from 1997 to 1999, served in various additional capacities. Prior to joining Barr, he was associated with the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell, and Reynolds, from 1989 to 1992. He also served as a Senior Consultant with Arthur Andersen & Co. Mr. Bisaro currently serves on the Board of Directors of Allergan, Zoetis, Inc. and on the Board of Visitors of the Catholic University of America’s Columbus School of Law. He also served as Chairman of the Board of the Generic Pharmaceutical Association (GPhA) in 2010 and 2011.
Mr. Bisaro received his undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from the Catholic University of America in Washington, D.C.
“At Impax, we support efforts to make medicines accessible to those who need them. To help, we established a Patient Assistance Program in 2012. Since inception, we have provided our medications to thousands of patients in need at no cost.”